nitroglycerin has been researched along with Neoplasms in 19 studies
Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.
nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.
nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine analgesia and adverse effects following transdermal application of nitroglycerine (a nitric oxide generator) combined with oral morphine, in cancer pain patients." | 9.10 | Double-blind evaluation of transdermal nitroglycerine as adjuvant to oral morphine for cancer pain management. ( Lauretti, GR; Pereira, NL; Perez, MV; Reis, MP, 2002) |
| "Nitroglycerin (NTG) is a prodrug that has long been used in clinical practice for the treatment of angina pectoris." | 5.41 | Nitroglycerin: a comprehensive review in cancer therapy. ( Bettaieb, A; Meunier, M; Plenchette, S; Yammine, A, 2023) |
| "To examine analgesia and adverse effects following transdermal application of nitroglycerine (a nitric oxide generator) combined with oral morphine, in cancer pain patients." | 5.10 | Double-blind evaluation of transdermal nitroglycerine as adjuvant to oral morphine for cancer pain management. ( Lauretti, GR; Pereira, NL; Perez, MV; Reis, MP, 2002) |
| "The morphine regimen was adjusted individually to a maximal oral dose of 80-90 mg/day to keep the visual analog scale score less than 4." | 2.69 | Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. ( Lauretti, GR; Lima, IC; Pereira, NL; Prado, WA; Reis, MP, 1999) |
| "Data Sets for the identified cancers from the above procedure were obtained from GEO Database." | 1.62 | Integrative Bioinformatics approaches to therapeutic gene target selection in various cancers for Nitroglycerin. ( Chinnappan, J; Ramu, A; S, AK; V, VR, 2021) |
| "typhimurium A1-R on pancreatic cancer stem cells, on pancreatic cancer in combination with anti-angiogenic agents, as well as on cervical cancer, soft-tissue sarcoma, and pancreatic cancer patient-derived orthotopic xenograft (PDOX) mouse models, is also described." | 1.43 | Tumor-Targeting Salmonella typhimurium A1-R: An Overview. ( Hoffman, RM, 2016) |
| "Solid tumors exhibit the enhanced permeability and retention (EPR) effect for biocompatible macromolecules such as polymer-conjugated anticancer agents, liposomes, and micelles." | 1.43 | Enhancement of Tumor-Targeted Delivery of Bacteria with Nitroglycerin Involving Augmentation of the EPR Effect. ( Fang, J; Long, L; Maeda, H, 2016) |
| "Immune escape is a fundamental trait of cancer in which mechanistic knowledge is incomplete." | 1.40 | A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. ( Barsoum, IB; Graham, CH; Siemens, DR; Smallwood, CA, 2014) |
| "The potential for malignancy detection using dynamic infrared imaging (DIRI) has been investigated in an animal model of human malignancy." | 1.32 | Dynamic infrared imaging for the detection of malignancy. ( Button, TM; Carvelli, P; Dulaimy, K; Fisher, P; Geronimo, C; Geronimo, V; Jambawalikar, S; Li, H; Li, S; O'Hea, B; Rosenblatt, R; Salvitti, M; Weiss, R, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Helguera, AM | 1 |
| Cordeiro, MN | 1 |
| Pérez, MA | 1 |
| Combes, RD | 1 |
| González, MP | 1 |
| Chinnappan, J | 1 |
| Ramu, A | 1 |
| V, VR | 1 |
| S, AK | 1 |
| Meunier, M | 1 |
| Yammine, A | 1 |
| Bettaieb, A | 2 |
| Plenchette, S | 1 |
| Melissa, K | 1 |
| Anne-Marie, C | 1 |
| Hiba, D | 1 |
| Joel, R | 1 |
| Ying, J | 1 |
| Ruth A, R | 1 |
| Ray, H | 1 |
| Hirsch-Ginsberg, CF | 1 |
| Issam, RI | 1 |
| Chaftari, AM | 1 |
| Hachem, R | 1 |
| Szvalb, A | 1 |
| Taremi, M | 1 |
| Granwehr, B | 1 |
| Viola, GM | 1 |
| Amin, S | 1 |
| Assaf, A | 1 |
| Numan, Y | 1 |
| Shah, P | 1 |
| Gasitashvili, K | 1 |
| Natividad, E | 1 |
| Jiang, Y | 1 |
| Slack, R | 1 |
| Reitzel, R | 1 |
| Rosenblatt, J | 1 |
| Mouhayar, E | 1 |
| Raad, I | 1 |
| Islam, W | 1 |
| Fang, J | 3 |
| Imamura, T | 1 |
| Etrych, T | 1 |
| Subr, V | 1 |
| Ulbrich, K | 1 |
| Maeda, H | 4 |
| Barsoum, IB | 2 |
| Smallwood, CA | 1 |
| Siemens, DR | 2 |
| Graham, CH | 2 |
| Liao, L | 1 |
| Yin, H | 1 |
| Nakamura, H | 1 |
| Shin, T | 1 |
| Cortier, M | 1 |
| Boina-Ali, R | 1 |
| Racoeur, C | 1 |
| Paul, C | 1 |
| Solary, E | 1 |
| Jeannin, JF | 1 |
| Hoffman, RM | 1 |
| Long, L | 1 |
| Hamilton, TK | 1 |
| Li, X | 1 |
| Cotechini, T | 1 |
| Miles, EA | 1 |
| Cianci, G | 1 |
| Morelli, MF | 1 |
| Cannita, K | 1 |
| Morese, R | 1 |
| Ricevuto, E | 1 |
| Di Rocco, ZC | 1 |
| Porzio, G | 1 |
| Lanfiuti Baldi, P | 1 |
| Ficorella, C | 1 |
| Button, TM | 1 |
| Li, H | 1 |
| Fisher, P | 1 |
| Rosenblatt, R | 1 |
| Dulaimy, K | 1 |
| Li, S | 1 |
| O'Hea, B | 1 |
| Salvitti, M | 1 |
| Geronimo, V | 1 |
| Geronimo, C | 1 |
| Jambawalikar, S | 1 |
| Carvelli, P | 1 |
| Weiss, R | 1 |
| Lauretti, GR | 2 |
| Lima, IC | 1 |
| Reis, MP | 2 |
| Prado, WA | 1 |
| Pereira, NL | 2 |
| McDonnell, F | 1 |
| Walsh, D | 1 |
| Perez, MV | 1 |
| Ohno, K | 1 |
| Yamashita, M | 1 |
| Yamakawa, N | 1 |
| Akinoto, S | 1 |
| Takahashi, T | 1 |
| Kushima, K | 1 |
| Murakami, K | 1 |
| Tatei, T | 1 |
| Miyamoto, Y | 1 |
| Fujita, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1/2 Study to Evaluate the Safety and Effectiveness of Novel Non-Antibiotic, Non-Heparin Nitroglycerin Based Catheter Lock Solution Used for the Prevention of Intraluminal Central Venous Catheter (CVC) Infections in Cancer Patients[NCT02577718] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| Pilot Study to Test the Feasibility of IV Injected Tc-99m-tilmanocept for Imaging of M2-like Tumour Associated Macrophages in Metastatic Melanoma[NCT04663126] | Early Phase 1 | 5 participants (Actual) | Interventional | 2021-02-01 | Terminated (stopped due to after inclusion of 5 patients, tracer had low uptake (kidney/liver)) | ||
| Study of the Efficiency of the Ketamine With Low Analgesic Doses, in Association With High Opioids, in the Treatment of the Rebels Pains, in Palliative Phase of the Cancerous Disease[NCT01326325] | Phase 3 | 24 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Catheter-Associated Infections will be measured by microbiological culture defined as either Catheter-Related Bloodstream Infection (CRBSI) as defined by the Infectious Diseases Society of America (IDSA), particularly in neutropenic patients, or Central Line-Associated Bloodstream Infection (CLABSI) as defined by the Centers for Disease Control and Prevention (CDC), particularly in non-neutropenic patients (NCT02577718)
Timeframe: 60 Days
| Intervention | infections per 1000 catheter days (Number) |
|---|---|
| NiCE Lock | 0 |
| Off NiCE Lock | 1.6 |
Drug-related hypotension is defined as a significant drop in measured blood pressure (BP) that exceeds the normal BP variability of a patient by 30%, that is associated with clinical signs and symptoms (dizziness and syncope) and is unexplained by factors other than the lock solution (such as other antihypertensive drugs, sepsis, bleeding). BP variability will be based on the standard deviation (SD) of a patient's blood pressure measured in the 3 days preceding participation in this trial and will be calculated at the time of trial entry. (NCT02577718)
Timeframe: From date of randomization until date of first Drug-Related Hypotension within 10 minutes of each flush, assessed up to 60 days
| Intervention | Participants (Count of Participants) |
|---|---|
| NiCE Lock | 0 |
1 review available for nitroglycerin and Neoplasms
| Article | Year |
|---|---|
Nitroglycerin: a comprehensive review in cancer therapy.
Topics: Angina Pectoris; Humans; Neoplasms; Nitric Oxide; Nitroglycerin | 2023 |
2 trials available for nitroglycerin and Neoplasms
| Article | Year |
|---|---|
Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Humans; Ke | 1999 |
Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Humans; Ke | 1999 |
Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Humans; Ke | 1999 |
Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Humans; Ke | 1999 |
Double-blind evaluation of transdermal nitroglycerine as adjuvant to oral morphine for cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Double-Blind Method; Drug Syner | 2002 |
16 other studies available for nitroglycerin and Neoplasms
| Article | Year |
|---|---|
QSAR modeling of the rodent carcinogenicity of nitrocompounds.
Topics: Animals; Drug Evaluation, Preclinical; Female; Neoplasms; Nitro Compounds; Quantitative Structure-Ac | 2008 |
Integrative Bioinformatics approaches to therapeutic gene target selection in various cancers for Nitroglycerin.
Topics: Computational Biology; Gene Expression Regulation, Neoplastic; Gene Ontology; Gene Regulatory Networ | 2021 |
Efficacy of a nitroglycerin-citrate-ethanol lock solution in maintaining central venous catheter patency and preventing thrombotic occlusions in cancer patients.
Topics: Catheterization, Central Venous; Catheters, Indwelling; Central Venous Catheters; Citrates; Ethanol; | 2021 |
A Novel Nonantibiotic Nitroglycerin-Based Catheter Lock Solution for Prevention of Intraluminal Central Venous Catheter Infections in Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Catheter-Related Infections; Catheterization, Central Venous; Centra | 2017 |
Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines.
Topics: Animals; Antineoplastic Agents; Arginine; Disease Models, Animal; Doxorubicin; Female; Hydroxyurea; | 2018 |
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
Topics: Adaptive Immunity; Animals; Apoptosis; B7-H1 Antigen; Cell Line, Tumor; Cytotoxicity, Immunologic; F | 2014 |
Enhanced bacterial tumor delivery by modulating the EPR effect and therapeutic potential of Lactobacillus casei.
Topics: Animals; Electron Spin Resonance Spectroscopy; Enalapril; Female; Lacticaseibacillus casei; Male; Mi | 2014 |
H89 enhances the sensitivity of cancer cells to glyceryl trinitrate through a purinergic receptor-dependent pathway.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Gen | 2015 |
Tumor-Targeting Salmonella typhimurium A1-R: An Overview.
Topics: Amino Acids; Animals; Disease Models, Animal; Humans; Mice; Neoplasms; Nitric Oxide; Nitroglycerin; | 2016 |
Enhancement of Tumor-Targeted Delivery of Bacteria with Nitroglycerin Involving Augmentation of the EPR Effect.
Topics: Animals; Antineoplastic Agents; Bacteria; Disease Models, Animal; Drug Delivery Systems; Humans; Mac | 2016 |
Nitroglycerin enhances vascular blood flow and drug delivery in hypoxic tumor tissues: analogy between angina pectoris and solid tumors and enhancement of the EPR effect.
Topics: Angina Pectoris; Animals; Antineoplastic Agents; Blood Flow Velocity; Contrast Media; Coronary Circu | 2010 |
Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Animals; Blotting, Western; Cel | 2011 |
Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.
Topics: Aged; Angina Pectoris; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Male; Middle A | 2003 |
Dynamic infrared imaging for the detection of malignancy.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Humans; Image Processing, Compu | 2004 |
Treatment of odynophagia and dysphagia in advanced cancer with sublingual glyceryl trinitrate.
Topics: Administration, Sublingual; Deglutition Disorders; Female; Humans; Male; Middle Aged; Muscle Relaxat | 1999 |
[Effectiveness of pharmacoangiography using nitroglycerin and angiotensin II].
Topics: Angiography; Angiotensin II; Humans; Neoplasms; Nitroglycerin | 1989 |